Horus pharma

What Horus pharma does

Horus Pharma is an independent French ophthalmic pharmaceutical laboratory headquartered in Nice, founded in 2003 by the Claret family, and described as France's second-largest independent ophthalmic pharmaceutical company. The firm focuses on preservative-free ophthalmic formulations, marketing approximately 70 products across five categories: medicines, medical devices, human tissues, dietary supplements, and cosmetics. It serves ophthalmologists, optometrists, hospital eye departments, and patients with conditions ranging from dry eye and glaucoma to retinal pathologies, corneal healing, and rare ocular conditions.

The company's technology base is anchored by EPIFREE®, a proprietary low-temperature sterilization process that preserves active ingredient quality without preservatives, plus 17 patents filed around preservative-free multi-dose delivery. Manufacturing is anchored in Europe (75% in France, 100% in Europe), with R&D spending at 10% of revenue and approximately 20% of staff in research roles. The portfolio spans hyaluronic-acid dry-eye drops (VISMED®, NEOVIS®), preservative-free vitamin A ointment (HYDRAMED® NIGHT SENSITIVE), corneal cross-linking solutions and devices (RITSIGHT®, CHROMO4VIS®), contact-lens care (REGARD®), regenerative medicine based on autologous platelet-rich plasma (PRGF-ENDORET®), preservative-free glaucoma and anti-inflammatory products, and adjacent dermocosmetics (ILAST®, Clarté Laboratoire). The company has been based at Paris's Institut de la Vision since 2008 and is engaged in the Eco'Ophtalmo environmental program, with ISCC Plus certification and an EcoVadis Silver Medal (73/100 in 2025).

Horus Pharma generates revenue through direct sales via nine European subsidiaries covering France, Spain, Belgium-Luxembourg, the Netherlands, Northern Europe (Sweden, Norway, Finland, Denmark), Switzerland, Monaco, and Romania, complemented by distribution agreements spanning over 40 countries. Reported 2025 revenue was €116 million, with 15% generated internationally and an explicit goal to double that share within three years. Products are dispensed through pharmacies and ophthalmology practices, with reimbursement from national health systems (first French reimbursement secured in 2006). Strategic momentum includes a November 2025 licensing deal with Formycon to commercialize the BAIAMA® aflibercept biosimilar in selected European markets, eight new MENA distribution agreements signed in 2025, and entry into the MedFrance pharmaceutical SME association in April 2026.

Name

Horus pharma

Legal name

Horus Pharma SAS

Website

https://horus-pharma.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Independent French ophthalmic pharmaceutical laboratory founded in 2003 in Nice, specializing in preservative-free formulations across medicines, medical devices, dietary supplements, and cosmetics, serving ophthalmologists and patients in 9 European countries and 40+ distribution markets with 70+ products.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Biological Product (except Diagnostic) Manufacturing (325414), Ophthalmic Goods Merchant Wholesalers (42346)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE), Eye, Ear & Nasal Care (HLAIADAF)

Keywords

• Ophthalmic pharmaceuticals
• Preservative-free eye drops
• Dry eye treatments
• Ocular nutrition supplements
• Contact lens care solutions

Headquarters

HQ city

Saint-laurent-du-var

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical and Medical Device Products: Horus Pharma generates revenue through the sale of five product categories: Medicines, Medical Devices, Human Tissues, Dietary Supplements, and Cosmetics. Products are sold directly through subsidiaries in European markets and through distribution partners internationally.
2. Licensing and Distribution Agreements: Revenue is generated through licensing agreements for proprietary technologies (such as EPIFREE®) and commercial distribution agreements covering over 40 countries, including the 2025 aflibercept biosimilar agreement with Formycon for key European markets.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Horus Pharma develops, manufactures, and commercialises a portfolio of approximately 70 ophthalmic pharmaceutical and medical device products across five categories: Medicines (prescription drugs for dry eye, glaucoma, retinal diseases, infections, inflammation), Medical Devices (contact lens care solutions, corneal cross-linking devices, intraocular dyes), Human Tissues (amniotic membranes), Dietary Supplements (ocular nutrition), and Cosmetics (eyelid hygiene and facial care). The company specialises in preservative-free ophthalmic formulations sold under brands including VISMED®, NEOVIS®, DULCILARMES®, REGARD®, CHROMO4VIS®, and BAIAMA®.

Product overview

Horus Pharma is a leading French independent ophthalmic pharmaceutical laboratory and major European player with over 20 years of experience advancing eye care. The company operates across four product categories: Medicines (including dry eye medications like DULCILARMES® and glaucoma treatments like BRIMAZED®, BAIAMA®), Medical Devices (ophthalmic solutions VISMED® and NEOVIS® for dry eye, contact lens solutions REGARD®, cross-linking devices CHROMO4VIS® and RITSIGHT), Ocular Nutrition through its Dulcis health science subsidiary (dietary supplements including Macula-Z®, NaturOphta® range), and Dermocosmetics/Cosmetics (Ilast® products for eyelid care and Clarté Laboratoire® brand for facial care). The portfolio includes approximately 70 products, with the company pioneering preservative-free formulations since 2003, holding 17 patents, and dedicating 10% of revenue to R&D.

Differentiator

Problem solved

Functional benefit

Brands

• Clarté Laboratoire: First aesthetic brand to emerge from ophthalmology research, applying medical standards to facial care; offers preservative-free, fragrance-free cosmetics for eye contour and face in innovative refillable glass containers
• Dulcis Health Science
• Ilast

Products and services

• VISMED® MULTI Preservative-free ophthalmic solution containing 0.18% hyaluronic acid in a 15 mL multi-dose bottle for moderate to severe dry eye symptoms with viscoelastic and water-retention properties.
• VISMED® GEL MULTI Preservative-free ophthalmic hydrogel containing 0.3% hyaluronic acid in a 15 mL multi-dose bottle providing prolonged relief for dry eye conditions.
• VISMED® Preservative-free ophthalmic solution in unit-dose format containing 0.18% hyaluronic acid for moderate to severe dry eye.
• VISMED® GEL Preservative-free ophthalmic hydrogel in unit-dose format containing 0.3% hyaluronic acid for prolonged protection and maximum comfort for dry eye and ocular surface lesions.
• NEOVIS® TOTAL multi Preservative-free ophthalmic emulsion in 15 mL multi-dose bottle containing 0.18% sodium hyaluronate and phospholipids, stabilizing the tear film for moderate to severe dry eye.
• NEOVIS® TOTAL Sterile preservative-free ophthalmic emulsion in unit-dose format with 0.18% sodium hyaluronate, phospholipids, triglycerides, and alpha lipoic acid for lubricating and protecting the ocular surface.
• DULCILARMES® 10 mL flacon Multi-dose bottle medication containing 1.5% povidone for dry eye treatment; the company's first product launched in 2003.
• DULCILARMES® unidoses Unit-dose medication containing 1.5% povidone for preservative-free ocular lubrication and dry eye treatment.
• HYDRAMED® NIGHT SENSITIVE Preservative-free lubricating ophthalmic ointment in 5 g tube containing vitamin A (25,000 IU/100g), paraffin liquid, and petroleum jelly for overnight dry eye relief.
• RITSIGHT Class IIb medical device containing 0.22% riboflavin hypotonic ophthalmic solution used during corneal cross-linking procedures to protect internal eye structures from UV-A radiation damage.
• CHROMO4VIS® Class IIb electronic UV-A medical device emitting uniform circular UV-A light for theranostic corneal cross-linking procedures to treat keratoconus, corneal ectasia, bullous keratopathy, and infectious keratitis.
• REGARD® 355 mL Class IIb medical device contact lens care solution in 355 mL bottle using Oxychlorite® system for decontamination and maintenance of soft contact lenses.
• REGARD® 60 mL Class IIb medical device contact lens care solution in 60 mL bottle using Oxychlorite® system for sterile, isotonic lens maintenance.
• REGARD® Tripack 3 x 355 mL Class IIb medical device contact lens care solution pack containing three 355 mL bottles using the Oxychlorite® system.
• Macula-Z® Dietary supplement for ocular nutrition containing lutein, zeaxanthin, and antioxidants to help maintain normal vision and protect against oxidative stress.
• Macula-Z® Oro Oro-dispersible dietary supplement for ocular nutrition in 60 tablet pack with lutein, zeaxanthin, vitamin C, vitamin E, and selenium for easy intake.
• NaturOphta® Lacryma Ocular nutrition supplement containing 30 capsules with Maquibright® (maqui berry), inulin, zinc, vitamin D, and riboflavin to support vision and reduce oxidative stress.
• BAIAMA® Brand name for Formycon's aflibercept biosimilar FYB203 commercialised by Horus Pharma across selected European markets for treatment of wet age-related macular degeneration and other VEGF-mediated diseases.
• ILUVIEN® Intravitreal implant for diabetic macular edema treatment.
• BAIMAZED® Preservative-free glaucoma treatment product.
• BRIMAZED® Preservative-free glaucoma treatment product.
• OCUFEN® Preservative-free ophthalmic anti-inflammatory product.
• DEXOCOL® Preservative-free ophthalmic corticosteroid product.
• PRGF – ENDORET® Regenerative medicine product based on autologous plasma (platelet-rich growth factors) for patients with severe dry eye conditions where no other treatment options remain.
• ILAST SUNPROTECT Dermocosmetic sun protection product for eyelids and eye contour area, formulated with ophthalmological expertise.
• Ilast Hydraclean Dermocosmetic hygiene product for eyelids combining ophthalmological and dermatological expertise for sensitive eyelid care.
• Ilast Lingettes Wipes for eyelid hygiene formulated for sensitive and delicate eye contour areas, manufactured using EPIFREE® technology.
• Camolid Dermocosmetic product containing 15 unit doses of 5 mL chamomile floral water for daily eyelid hygiene of sensitive eyelids.
• Crème de jour raffermissante (Clarté Laboratoire) Cosmetic firming day cream in 30 mL airless bottle containing low molecular weight hyaluronic acid and ceramide NG for hydration and skin barrier preservation.
• Sérum anti-âge global haute concentration (Clarté Laboratoire) High-concentration anti-aging serum in 30 mL airless bottle targeting expression lines and wrinkles with dual hyaluronic acid and peptide combination.
• Contour des yeux multi-corrections (Clarté Laboratoire) Multi-correction eye contour care in 30 mL airless bottle targeting wrinkles, dark circles, and puffiness with acetyl hexapeptide-8, acetyl tetrapeptide-5, and hyaluronic acid.

Quantifiable outcome

• 100% of production carried out in Europe (75% in France)
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• Formycon AGcoreStrategic or Co-development Partner · 1 November 2025Horus Pharma signed a strategic agreement to commercialise Formycon's aflibercept biosimilar FYB203 under the brand name BAIAMA® across selected European countries. This expands Horus Pharma's ophthalmology portfolio in key European markets including its home market of France. The agreement follows Formycon's prior agreements with Klinge-Teva for major European markets and Israel.
• Plastic BanksupportingStrategic or Co-development PartnerCanadian social organisation partnership established at the end of 2022 to achieve plastic neutrality for approximately 30 Horus Pharma products. As of the latest report, 434 tonnes of plastic have been collected and recycled (equivalent to 21.7 million 50 cl bottles), supporting 2,044 people in local communities.
• Institut de la Vision (Paris)coreStrategic or Co-development PartnerHorus Pharma has been based at the Institut de la Vision in Paris since 2008, benefiting from this cutting-edge research environment. The institute is Europe's leading integrated research centre dedicated entirely to eye diseases, supported by INSERM and Université Pierre et Marie Curie. Researchers, clinicians, and industry partners collaborate to develop treatments and technological innovations.
• French Society of Ophthalmology (SFO)supportingStrategic or Co-development PartnerFive-year consecutive partnership with the French Society of Ophthalmology (SFO) to recognise young ophthalmologist projects. Since 2024, includes the Eco'Ophtalmo Award for ecological initiatives in ophthalmology. Awards presented annually at the SFO Congress to projects bridging research, innovation, and sustainable ophthalmological practice.
• CDMDOs (Contract Development and Manufacturing Organisations)supportingTechnology or IntegrationLong-term partnerships with Contract Development and Manufacturing Organisations (CDMOs) that share Horus Pharma's concern for the environment. These partnerships are based on joint efforts to reduce carbon footprint throughout the manufacturing process, strengthening a more sustainable value chain. 75% of products are manufactured in France and 100% in Europe.
• MedFrancesupportingStrategic or Co-development PartnerHorus Pharma joined MedFrance in April 2026, a trade association representing SMEs and mid-market companies in the pharmaceutical sector involved in European production of essential and established treatments. Around 40 companies share priorities: differentiated regulation for mature medicines, territorial and environmental criteria in pricing, and strengthening vigilance regarding regulatory standards impact on SMEs.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Laboratoires Théa: Independent French ophthalmic pharmaceutical laboratory and the largest independent player in France. Closely comparable to Horus Pharma given similar independence, preservative-free focus, French heritage, and ophthalmic therapeutic area focus across dry eye, glaucoma, and ocular surface disease.
• Nicox: French-headquartered ophthalmic company developing and commercialising therapeutics for ocular surface diseases and glaucoma. Closely comparable to Horus as a European independent ophthalmic R&D specialist with similar therapeutic focus and mid-market scale.
• Santen Pharmaceutical: Japanese-headquartered global specialty ophthalmic pharmaceutical company focused on prescription pharmaceuticals for dry eye, glaucoma, retinal diseases, and ocular allergies. Comparable to Horus as a dedicated ophthalmic specialist with European commercial presence and a portfolio centred on preservative-free and specialty formulations.

Broad incumbents

• Alcon: Global leader in eye care spanning surgical, vision care, and pharmaceutical products. Operates across the same ophthalmic therapeutic categories as Horus (dry eye, glaucoma, retinal) but at vastly larger scale; serves as both a competitive incumbent and a benchmark for portfolio breadth and innovation capacity.
• Bausch + Lomb: Global eye health company with pharmaceutical, surgical, and consumer vision care divisions, including preservative-free dry eye products and contact lens care solutions overlapping with Horus's VISMED and REGARD ranges. Comparable as a broad incumbent across Horus's full portfolio categories.
• Roche / Genentech: Global pharmaceutical major with a leading retinal therapeutics franchise (Lucentis, Vabysmo) directly competing with Horus's newly licensed aflibercept biosimilar (BAIAMA®) in the VEGF-mediated disease segment. Comparable as the dominant incumbent in retinal therapeutics where Horus is now competing via biosimilar entry.
• Allergan Aesthetics / AbbVie: Major global pharmaceutical player with a substantial ophthalmic franchise (formerly Allergan) spanning dry eye, glaucoma, and retinal therapeutics. Comparable as a broad incumbent competing with Horus across multiple therapeutic categories, though at significantly larger scale and with greater R&D resources.

Emerging players

• Novaliq: German biopharmaceutical company developing preservative-free ophthalmic therapies based on water-free technology. Comparable to Horus as an emerging specialist in preservative-free ophthalmic innovation, with overlap in dry eye therapeutics and novel formulation approaches.
• Ocular Therapeutix: US-based biopharmaceutical company developing ophthalmic therapeutics with a focus on drug delivery platforms and preservative-free formulations, including treatments for dry eye and post-surgical inflammation. Comparable to Horus in its preservative-free and drug delivery innovation emphasis, though operating primarily in US markets.

Regional players

• Rayner Surgical Group: UK-headquartered ophthalmic company with intraocular lenses and ophthalmic solutions, including viscoelastic and dry eye products. Comparable to Horus as a mid-sized European ophthalmic specialist with overlapping product categories, though with a stronger surgical device focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@HorusPharmaGroup
• LinkedInlinkedin.com/company/horus-pharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries8 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Horus pharma